Foundation Medicine Inc (NASDAQ:FMI) COO Konstantin Fiedler sold 358 shares of the firm’s stock in a transaction dated Monday, April 2nd. The shares were sold at an average price of $74.88, for a total transaction of $26,807.04. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Shares of NASDAQ:FMI opened at $72.25 on Friday. Foundation Medicine Inc has a twelve month low of $29.90 and a twelve month high of $87.10. The company has a current ratio of 1.86, a quick ratio of 1.67 and a debt-to-equity ratio of 1.90.
Foundation Medicine (NASDAQ:FMI) last released its earnings results on Wednesday, March 7th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). Foundation Medicine had a negative return on equity of 207.73% and a negative net margin of 105.60%. The firm had revenue of $48.90 million for the quarter, compared to the consensus estimate of $48.69 million. During the same quarter in the previous year, the business posted ($1.02) EPS. Foundation Medicine’s revenue was up 69.8% on a year-over-year basis. sell-side analysts predict that Foundation Medicine Inc will post -4.22 earnings per share for the current year.
FMI has been the topic of a number of recent analyst reports. Cowen initiated coverage on shares of Foundation Medicine in a report on Thursday, February 15th. They set an “outperform” rating and a $90.00 price target on the stock. Goldman Sachs initiated coverage on shares of Foundation Medicine in a research note on Monday, January 29th. They issued a “neutral” rating and a $73.00 price objective on the stock. Zacks Investment Research cut shares of Foundation Medicine from a “buy” rating to a “sell” rating in a research note on Wednesday, January 3rd. BidaskClub upgraded shares of Foundation Medicine from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. Finally, Wells Fargo reiterated a “market perform” rating and issued a $80.00 price objective (up previously from $67.00) on shares of Foundation Medicine in a research note on Thursday, March 8th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $69.60.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3334609/konstantin-fiedler-sells-358-shares-of-foundation-medicine-inc-fmi-stock.html.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.